As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on March 10 and set a price target of ...

Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2 ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.